Patents
Breakthrough for Can-Fite: CF102 Found to be Active Against Hepatitis B Virus in Pre-Clinical Studies
Published in Hepatitis Weekly, March 5th, 2007
Can-Fite BioPharma (TASE:CFBI) a biotechnology company traded on the Tel-Aviv Stock Exchange. The Company's pre-clinical studies show that CF102 is also active against Hepatitis B virus, in addition to liver cancer, which is the first indication being developed. The new discovery opens up for Can-Fite a potentially significant target market of approximately 3 billion dollars, and may lead to the accelerated development of CF102, which Can-Fite is developing alongside its first drug, CF101, which is already in various phases of clinical trials in the United States, Europe and Israel.
The new findings were obtained in collaboration with the laboratory of Dr. Kamel...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-03-05)
More Articles from Hepatitis Weekly
- Cancer Vaccines
World Vaccine Market Offers Promise of Growth Exceeding $15 Billion in 2012! - Gene Therapy
RNAi Shows Promise in Gene Therapy, Stanford Researcher Says - Hepatitis
Dynavax Announces Fourth Quarter and Year End 2006 Financial Results - Hepatitis B Virus
Sinovac Files Registration Documents for Euvax-B with SFDA Loan Repayment Received from One Former Director - Hepatitis C Virus
CLINICAL PHASE I TRIAL WITH HEPATITIS C VIRUS PROTEASE INHIBITOR INITIATED - Hepatitis C Virus
Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
